<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285077</url>
  </required_header>
  <id_info>
    <org_study_id>LTS5283</org_study_id>
    <nct_id>NCT00285077</nct_id>
  </id_info>
  <brief_title>Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease</brief_title>
  <official_title>Long-Term Safety Extension of Phase II Study EFC5286 of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective is to assess the long term safety/tolerability of 4 mg/day of SR57667B
      in comparison to placebo in patients with mild-to-moderate Alzheimer's Disease (AD).

      A secondary objective is to describe the long term progression of Alzheimer's symptoms in
      patients treated by 4 mg/day of SR57667B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multinational, multicenter, randomized, parallel-group, double-blind, phase II study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events recorded quarterly.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADAS-cog, CDR, MMSE, CGIC, ADCS-ADL, NPI measured at baseline and at 2,6,9 and 12 months.</measure>
  </secondary_outcome>
  <enrollment type="Actual">390</enrollment>
  <condition>Alzheimer Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR57667B</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have participated in Study EFC5286 and completed the study.

          -  Patient, identified caregiver and, if applicable, patient surrogate (primary relative,
             legal guardian, medical proxy) have given their informed written consent and are
             capable of following study procedures specifically for this LTS5283 extension.

        Exclusion Criteria:

          -  Females who are pregnant or breast-feeding.

          -  Females of child bearing potential (premenopausal female biologically capable of
             becoming pregnant) must have a confirmed negative serum b-HCG pregnancy test at the
             screening visit,and must use an acceptable method of birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge GAUTHIER, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Advisory Committee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marc ORGOGOZO, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Advisory Committee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip SCHELTENS, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Advisory Committee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bengt WINBLAD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Advisory Committee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horslholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>South Africa</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <last_update_submitted>December 22, 2008</last_update_submitted>
  <last_update_submitted_qc>December 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Alzheimer disease</keyword>
  <keyword>nerve growth factors</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

